Dr.Β FrederickΒ Locke
MD, Hematology/Oncology Fellowship
Chair, Blood & Marrow Transplant and Cellular Immunotherapy
corporate_fareMoffitt Cancer Center, Tampa, Florida, USA
Frederick Locke
MD, Hematology/Oncology Fellowship
Dr. Frederick L. Locke is a leading medical oncologist and translational researcher at Moffitt Cancer Center in Tampa, Florida, where he serves as Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy. He is internationally recognised for pioneering clinical research in CAR T-cell therapy for aggressive blood cancers, particularly relapsed or refractory large B-cell lymphoma.
Dr. Locke completed his MD at Wayne State University School of Medicine and undertook advanced Hematology/Oncology fellowship training at the University of Chicago Medical Center, where he also trained in clinical and laboratory research. At Moffitt Cancer Center, he leads the Immune Cell Therapy initiative β an integrated translational programme dedicated to developing and refining cell-based cancer treatments. He served as national principal investigator for the pivotal ZUMA-1 and ZUMA-7 clinical trials, which contributed to the FDA approval of axicabtagene ciloleucel (axi-cel) for aggressive lymphoma and established it as a standard treatment option. His published work appears in leading journals including The New England Journal of Medicine, Nature Medicine, and Journal of Clinical Oncology. In 2025, Moffitt Cancer Center honoured him with the W. Jackson Pledger Researcher of the Year Award for his contributions to cancer research.
CancerFax can coordinate medical-report review, case preparation, and consultation support for international patients seeking a specialist opinion or second opinion from Dr. Locke at Moffitt Cancer Center.
Why Consider Dr. Frederick Locke?
Dr. Locke is one of the most recognised figures in CAR T-cell therapy worldwide, combining deep clinical expertise with a track record of landmark translational research that has directly shaped how aggressive blood cancers are treated globally.
Areas of Specialisation
Advanced cellular immunotherapy, transplantation, and blood cancer care
Dr. Locke's clinical and research focus spans CAR T-cell therapy, blood and marrow transplantation, and the treatment of lymphoma, multiple myeloma, and leukaemia. His work bridges laboratory science and patient care, with a particular emphasis on understanding and overcoming resistance to cellular therapies.
CAR T-Cell Therapy & Cellular Immunotherapy
Pioneering clinical and translational work in chimeric antigen receptor T-cell therapies for blood cancers.
- arrow_rightAxicabtagene ciloleucel (axi-cel) for relapsed or refractory large B-cell lymphoma
- arrow_rightPatient selection, eligibility assessment, and treatment planning for CAR T-cell therapy
- arrow_rightManagement of CAR T-cell therapy toxicities including CRS and neurotoxicity
- arrow_rightClinical trial-based cellular immunotherapy for multiple myeloma
- arrow_rightNovel CAR T-cell constructs and combination immunotherapy strategies
- arrow_rightMoffitt's Immune Cell Therapy initiative for next-generation cell therapies
Blood & Marrow Transplantation
Comprehensive autologous and allogeneic stem cell transplant programmes for haematological malignancies.
- arrow_rightHigh-dose chemotherapy and autologous haematopoietic stem cell rescue
- arrow_rightConditioning regimen selection and transplant planning for eligible patients
- arrow_rightDonor-matched allogeneic transplant for haematological malignancies
- arrow_rightGraft-versus-host disease (GvHD) management and post-transplant care
Lymphoma & Haematological Malignancies
Clinical management of aggressive and indolent blood cancers with an emphasis on relapsed or refractory disease.
- arrow_rightDiffuse large B-cell lymphoma (DLBCL) treatment sequencing
- arrow_rightPrimary mediastinal B-cell lymphoma and high-grade B-cell lymphoma
- arrow_rightTransformed follicular lymphoma
- arrow_rightMultiple myeloma and plasma cell disorders
- arrow_rightLeukaemia management including cellular therapy approaches
- arrow_rightInvestigational survivin tumour vaccine strategy for myeloma
Procedures & Treatments
Cell-based therapies, transplantation, and immunotherapy-based cancer treatment
Dr. Locke's clinical practice covers the full spectrum of cellular immunotherapy and haematopoietic stem cell transplantation, with a strong emphasis on CAR T-cell therapy for patients with relapsed or treatment-resistant blood cancers.
CAR T-Cell Therapy Administration
Medical OncologyEnd-to-end management of anti-CD19 and investigational CAR T-cell therapies, including eligibility review, infusion, and toxicity monitoring.
Haematopoietic Stem Cell Transplant
TransplantAutologous and allogeneic stem cell transplantation for eligible patients with haematological malignancies.
Clinical Trial-Based Immunotherapy
Targeted TherapyInvestigational cellular and immune-based therapies for lymphoma, myeloma, and leukaemia through Moffitt's clinical trial programme.
Second Opinion β Blood Cancer
Second OpinionIndependent expert review for patients with lymphoma, myeloma, leukaemia, or CAR T-cell therapy eligibility questions.
Research & Publications
Translational research leadership in CAR T-cell therapy and cellular immunotherapy
Dr. Locke is a prolific translational researcher whose work has directly influenced clinical practice in CAR T-cell therapy. His research focuses on expanding the reach of cellular immunotherapy, understanding resistance mechanisms, and developing novel approaches for lymphoid malignancies and multiple myeloma.
Dr. Locke leads Moffitt's Immune Cell Therapy initiative and is an active clinical trial investigator. CancerFax can assess patient eligibility for open trials and facilitate submission of case materials for evaluation.
Education & Training
Dr. Locke completed his undergraduate training at Michigan State University, earned his MD at Wayne State University School of Medicine, and received advanced hematology/oncology fellowship training at the University of Chicago Medical Center.
Clinical Experience
Dr. Locke has spent his career at Moffitt Cancer Center, where he has built and now leads one of the most prominent cellular immunotherapy programmes in the United States, including translational laboratory research, clinical trial leadership, and direct patient care for complex haematological malignancies.
Languages & International
Dr. Locke conducts consultations in English.
CancerFax can coordinate professional medical interpreter support for international patients requiring assistance in languages other than English.
CancerFax can coordinate professional medical interpreter support for international patients consulting in other languages.
How CancerFax Helps You Access Dr. Frederick Locke
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Frederick Locke's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Frederick Locke's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Frederick Locke before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Frederick Locke's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Frederick Locke's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Frederick Locke's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Frederick Locke
Dr. Locke specialises in CAR T-cell therapy, cellular immunotherapy, blood and marrow transplantation, and the treatment of blood cancers including lymphoma, multiple myeloma, and leukaemia. He is particularly recognised for his work in treating relapsed or refractory aggressive B-cell lymphoma using axicabtagene ciloleucel.
Dr. Locke is based at Moffitt Cancer Center in Tampa, Florida, USA β a National Cancer Institute-designated comprehensive cancer centre. He serves as Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy.
CancerFax can coordinate medical-report review and consultation support for international patients seeking a specialist opinion or second opinion from Dr. Locke, subject to hospital availability and case acceptance. Please submit your reports through CancerFax and the team will manage the next steps.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your case documents, prepare a structured case summary, and coordinate the consultation pathway with Moffitt Cancer Center, subject to the doctor's availability.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling results, imaging, and prior treatment history. Dr. Locke's team can assess CAR T-cell therapy eligibility, treatment sequencing, and transplant candidacy. The final consultation format and availability depend on Moffitt Cancer Center's processes.
ZUMA-1 was a pivotal clinical trial evaluating axicabtagene ciloleucel CAR T-cell therapy in patients with refractory aggressive non-Hodgkin lymphoma. Dr. Locke served as national principal investigator for the trial, and the results contributed to FDA approval of axi-cel as a standard treatment option for relapsed or refractory large B-cell lymphoma.
Connect with Frederick Locke Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.